高磷血症是慢性肾脏病(Chronic kidney disease, CKD)和终末期肾病(end state rental disease, ESRD)患者透析患者常见的并发症之一,我国透析患者高磷血症患病率很高,但透析患者的血磷达标率却很低。而高磷血症可增加CKD患者心血管死亡率和全因死亡率。因此将血磷水平控制至目标水平是改善CKD患者预后的关键,我国近期新上市一种口服铁基非含钙磷结合剂以治疗透析患者高磷血症。本研究主要综述了高磷血症的发生机制及蔗糖羟基氧化铁治疗高磷血症的有效性、安全性,以期为蔗糖羟基氧化铁治疗高磷血症提供证据支持。Hyperphosphatemia is one of the common complications of dialysis patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Hyperphosphatemia can increase cardiovascular mortality and all-cause mortality in patients with CKD. Therefore, controlling the blood phosphorus level to the target level is the key to improving the prognosis of CKD patients, and an oral iron-based non-calcium-phosphorus binder has recently been launched in China to treat hyperphosphatemia in dialysis patients. This study mainly reviewed the mechanism of hyperphosphatemia and the efficacy and safety of sucrose sucroferric oxyhydroxide in the treatment of hyperphosphatemia, in order to provide evidence support for the treatment of hyperphosphatemia with sucrose sucroferric oxyhydroxide.
